703 results match your criteria: "and Dalhousie University[Affiliation]"

Background: Acute chest syndrome (ACS) is a leading cause of morbidity and mortality in sickle cell patients, and it is often challenging to establish its diagnosis.

Procedure: This was a prospective observational study conducted in a pediatric emergency (PEM) department. We aimed to investigate the performance characteristics of point-of-care lung ultrasound (LUS) for diagnosing ACS in sickle cell children.

View Article and Find Full Text PDF

We performed a systematic review and meta-analysis of the literature to evaluate the efficacy of the routine use of tranexamic acid (TXA) during percutaneous nephrolithotomy (PCNL). This systematic review was conducted following the updated reporting guidelines from PRISMA 2020. In total, 275 titles and abstracts were reviewed, of which 20 were screened to be eligible for full text review.

View Article and Find Full Text PDF

Updates on Juvenile Dermatomyositis from the Last Decade: Classification to Outcomes.

Rheum Dis Clin North Am

November 2021

University of California, San Francisco, 550 16th Street, San Francisco, CA 94158, USA.

Juvenile dermatomyositis (JDM) is a heterogeneous disease with new classification criteria and updates in myositis-specific autoantibody and myositis-associated antibody groups. There are many validated assessment tools for assessing disease activity in JDM. Future studies will optimize these tools and improve feasibility in clinical and research contexts.

View Article and Find Full Text PDF

Purpose: To identify factors associated with false or indeterminate US result for suspected appendicitis, and assess whether multi-categorical reporting of US yields more precise estimates regarding the probability of appendicitis.

Methods: 562 US examinations for suspected appendicitis between May 2013-April 2015 were categorized as true (77/562 true positives or true negatives) or false/indeterminate (485/562 false negatives, false positives or indeterminates) based on results from a prior study. Of 541 examinations with images available retrospectively, a category of A-E was assigned as follows: non-visualized appendix with secondary findings (A) absent or (B) present; appendix visualized and considered (C) negative, (D) equivocal, or (E) positive for appendicitis.

View Article and Find Full Text PDF

Objective: To evaluate the oncologic and functional outcomes of transoral laser microsurgery (TLM) for glottic cancers in patients ≥80 years.

Study Design: Prospectively collected case series.

Setting: QEII Health Sciences Centre, Halifax, Canada.

View Article and Find Full Text PDF

Assessment of Canadian Hospital Pharmacists' Job Satisfaction and Impact of Clinical Pharmacy Key Performance Indicators.

Can J Hosp Pharm

January 2021

, BSc(Pharm), ACPR, CHC, is with Pharmacy Services, Horizon Health Network, Saint John, New Brunswick.

Background: The clinical pharmacy key performance indicators (cpKPIs) are quantifiable measures of quality to advance clinical pharmacy practice and improve patient care. Although when delivered in combination they have been linked to important patient outcomes, no data are available relating to their impact on hospital pharmacists' job satisfaction.

Objectives: To determine the level of job satisfaction among Canadian hospital pharmacists and whether participation in cpKPI activities contributes to hospital pharmacists' job satisfaction.

View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to validate the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) and evaluate its effectiveness in predicting organ damage over time in patients with systemic lupus erythematosus (SLE).
  • - Researchers conducted a secondary analysis on data from 185 adult women with SLE, specifically tracking 149 patients over a 5-year follow-up period, calculating SLICC-FI and SLICC/ACR Damage Index scores.
  • - Results indicated that a higher baseline SLICC-FI score correlated with increased odds (28% higher) of organ damage over the subsequent five years, highlighting the importance of frailty assessment in these patients.
View Article and Find Full Text PDF

Objective: The management of peritonsillar abscess (PTA) has evolved over time. We sought to define contemporary practice patterns for the diagnosis and treatment of PTA.

Study Design: Cross-sectional survey.

View Article and Find Full Text PDF

Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer.

Lung Cancer

October 2021

Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.

Patients with non-small cell lung cancer (NSCLC) harboring ROS proto-oncogene 1 (ROS1) gene rearrangements show dramatic response to the tyrosine kinase inhibitor (TKI) crizotinib. Current best practice guidelines recommend that all advanced stage non-squamous NSCLC patients be also tested for ROS1 gene rearrangements. Several studies have suggested that ROS1 immunohistochemistry (IHC) using the D4D6 antibody may be used to screen for ROS1 fusion positive lung cancers, with assays showing high sensitivity but moderate to high specificity.

View Article and Find Full Text PDF

The doubling time (DT) of the BCR-ABL1 quantitative polymerase chain reaction (qPCR) transcript level reflects the re-growing fraction of leukaemic cells after discontinuation of tyrosine kinase inhibitor (TKI). The present study analyzed monthly DT within six months after imatinib discontinuation in 131 patients. Monthly DT was calculated as x = ln(2)/K, where x is the DT and K is the fold BCR-ABL1 change from the previous value divided by the number of days between each measurement.

View Article and Find Full Text PDF

A number of studies have demonstrated that patients with autoimmune disease have lower levels of vitamin D prompting speculation that vitamin D might suppress inflammation and immune responses in children with juvenile idiopathic arthritis (JIA).  The objective of this study was to compare vitamin D levels in children with JIA at disease onset with healthy children. We hypothesized that children and adolescents with JIA have lower vitamin D levels than healthy children and adolescents.

View Article and Find Full Text PDF

Objective: To develop a standardized steroid dosing regimen (SSR) for physicians treating childhood-onset systemic lupus erythematosus (SLE) complicated by lupus nephritis (LN), using consensus formation methodology.

Methods: Parameters influencing corticosteroid (CS) dosing were identified (step 1). Data from children with proliferative LN were used to generate patient profiles (step 2).

View Article and Find Full Text PDF

Background: Physical activity (PA) patterns in children with juvenile idiopathic arthritis (JIA) over time are not well described. The aim of this study was to describe associations of physical activity (PA) with disease activity, function, pain, and psychosocial stress in the 2 years following diagnosis in an inception cohort of children with juvenile idiopathic arthritis (JIA).

Methods: In 82 children with newly diagnosed JIA, PA levels, prospectively determined at enrollment, 12 and 24 months using the Physical Activity Questionnaire for Children (PAQ-C) and Adolescents (PAQ-A) raw scores, were evaluated in relation to disease activity as reflected by arthritis activity (Juvenile Arthritis Disease Activity Score (JADAS-71)), function, pain, and psychosocial stresses using a linear mixed model approach.

View Article and Find Full Text PDF

Signs of diastolic dysfunction are graded by serum testosterone levels in aging C57BL/6 male mice.

Mech Ageing Dev

September 2021

Department of Pharmacology, Dalhousie University, Halifax, NS, Canada; Department of Medicine (Geriatric Medicine), Dalhousie University, Halifax, NS, Canada. Electronic address:

We investigated whether maladaptive, age-associated changes in heart structure and function were linked to circulating testosterone levels. Male C57BL/6 mice had a gonadectomy (GDX) or sham surgery at 4 weeks and effects of GDX on the heart were examined with echocardiography. Serum testosterone was measured with ELISA.

View Article and Find Full Text PDF

Specimen oriented intraoperative margin assessment in oral cavity and oropharyngeal squamous cell carcinoma.

J Otolaryngol Head Neck Surg

June 2021

Department of Surgery, Division of Otolaryngology - Head and Neck Surgery, Queen Elizabeth II Health Science Centre and Dalhousie University, 3rd Floor Dickson Building, VG Site, 5820 University Avenue, Halifax, Nova Scotia, B3H 2Y9, Canada.

Objective: Evaluate the oncologic outcomes and cost analysis of transitioning to a specimen oriented intraoperative margin assessment protocol from a tumour bed sampling protocol in oral cavity (OCSCC) and oropharyngeal squamous cell carcinoma (OPSCC).

Study Design: Retrospective case series and subsequent prospective cohort study SETTING: Tertiary care academic teaching hospital SUBJECTS AND METHODS: Retrospective case series of all institutional T1-T2 OCSCC or OPSCC treated with primary surgery between January 1st 2009 - December 31st 2014. Kaplan-Meier survival estimates with log rank tests were used to compare patients based on final margin status.

View Article and Find Full Text PDF

Independent primary cutaneous and mammary apocrine carcinomas with neuroendocrine differentiation: Report of a case and literature review.

J Cutan Pathol

November 2021

Department of Pathology and Laboratory Medicine, Nova Scotia Health Authority (Central Zone), Halifax, Nova Scotia, Canada.

Cutaneous apocrine carcinomas share common features with their counterparts in the breast; hence, metastatic mammary carcinoma must be excluded before such lesions can be designated primary cutaneous neoplasms. Primary tumors from either source rarely exhibit neuroendocrine differentiation. We report a case of a 72-year-old female with a painless 1.

View Article and Find Full Text PDF

Therapeutic options for CTLA-4 insufficiency.

J Allergy Clin Immunol

February 2022

Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center, Faculty of Medicine, Albert Ludwig University of Freiburg, Freiburg, Germany; Department of Rheumatology and Clinical Immunology, Medical Center, Faculty of Medicine, Albert Ludwig University of Freiburg, Freiburg, Germany; Institute of Immunology and Transplantation, Royal Free Hospital, University College London, London, United Kingdom; Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Royal Manchester Children's Hospital, Manchester, United Kingdom; German Center for Infection Research, Satellite Center Freiburg, Freiburg, Germany; Centre for Integrative Biological Signaling Studies, Albert Ludwig University of Freiburg, Freiburg, Germany; RESIST-Cluster of Excellence 2155 to Hannover Medical School, Satellite Center Freiburg, Freiburg, Germany. Electronic address:

Background: Heterozygous germline mutations in cytotoxic T lymphocyte-associated antigen-4 (CTLA4) impair the immunomodulatory function of regulatory T cells. Affected individuals are prone to life-threatening autoimmune and lymphoproliferative complications. A number of therapeutic options are currently being used with variable effectiveness.

View Article and Find Full Text PDF

Rapid COVID-19 testing: Speed, quality and cost. Can you have all three?

Clin Biochem

September 2021

Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

KEY MESSAGES.

View Article and Find Full Text PDF

Objective: To determine predictors of change in neuropsychiatric (NP) event status in a large, prospective, international inception cohort of patients with systemic lupus erythematosus (SLE).

Methods: Upon enrollment and annually thereafter, NP events attributed to SLE and non-SLE causes and physician-determined resolution were documented. Factors potentially associated with the onset and resolution of NP events were determined by time-to-event analysis using a multistate modeling structure.

View Article and Find Full Text PDF

Background: Between-country variation in health care resource use and its impact on outcomes in acute care settings have been challenging to disentangle from illness severity by using administrative data.

Methods: We conducted a preplanned analysis employing patient-level emergency department (ED) data from children enrolled in 2 previously conducted clinical trials. Participants aged 3 to <48 months with <72 hours of gastroenteritis were recruited in pediatric EDs in the United States ( = 10 sites; 588 participants) and Canada ( = 6 sites; 827 participants).

View Article and Find Full Text PDF

Acute central nervous system (CNS) injury, such as stroke, spinal cord injury, or traumatic brain injury can result in dysregulated immune response, and the condition is known as CNS injury-induced immunodeficiency syndrome (CIDS). The endocannabinoid system is an important homeostatic regulator in the CNS and immune system. Activation of cannabinoid 2 receptors (CB2R) on immune cells has been reported to dampen inflammation, suggesting a potential role of CB2R in the peripheral immune response following CNS injury.

View Article and Find Full Text PDF

Bimekizumab versus Secukinumab in Plaque Psoriasis.

N Engl J Med

July 2021

From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen's University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) - all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.).

Article Synopsis
  • Bimekizumab is a monoclonal antibody that targets both interleukin-17A and interleukin-17F, and its effectiveness in treating moderate-to-severe plaque psoriasis compared to secukinumab (which targets only interleukin-17A) is unclear.
  • In a phase 3b trial involving 743 patients, participants were assigned to receive either bimekizumab or secukinumab, and the main measure of success was a 100% reduction in the Psoriasis Area and Severity Index (PASI) score by week 16.
  • Results showed that 61.7% of those on bimekizumab achieved PASI 100 by week 16,
View Article and Find Full Text PDF

Bimekizumab versus Adalimumab in Plaque Psoriasis.

N Engl J Med

July 2021

From the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester National Institute for Health Research Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); Oregon Medical Research Center, Portland (A.B.); Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Probity Medical Research and K. Papp Clinical Research, Waterloo, ON (K.A.P.), and Dalhousie University, Halifax, NS (R.G.L.) - both in Canada; Dermatology Institute and Skin Care Center, Santa Monica, CA (P.Y.); the Division of Dermatology, David Geffen School of Medicine at University of California, Los Angeles (P.Y.), and the Department of Dermatology, Keck School of Medicine, University of Southern California (A.A.) - both in Los Angeles; UCB Pharma, Brussels (V.V., D.D.C.); UCB Pharma, Raleigh, NC (C.C., L.P., N.C.); and the Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.).

Article Synopsis
  • - Bimekizumab is a monoclonal antibody that targets interleukin-17A and interleukin-17F, and its effectiveness compared to adalimumab (a TNF inhibitor) in treating moderate-to-severe plaque psoriasis was investigated.
  • - In a study involving 478 patients, those receiving bimekizumab saw significantly higher rates of improvement (86.2% achieving a 90% reduction in PASI score) compared to those on adalimumab (47.2%).
  • - The results indicated that bimekizumab not only met noninferiority standards but also demonstrated superior efficacy, providing stronger evidence for its use in psoriasis treatment.
View Article and Find Full Text PDF